Introduction: 64Cu-pyruvaldehyde-bis(N4- methylthiosemicarbazone) (64Cu-PTSM) is one of the most important copper radiopharmaceuticals used in clinical experiments. Methods: In this work, copper-64 (T1/2=12.33 h) production has been presented followed by the synthesis of the complexing agent, PTSM, and its structure was confirmed by common spectroscopic methods followed by radiolabeling with 64Cu- actetate. The tracer was finally administered to fibrosarcoma-bearing rats and the biodistribution was determined in critical tissues as well as tumor. Results: The final radiopharmaceutical solution underwent common quality control tests for animal injection a radiochemical purity >95% was determined. A significant tracer tumor uptake was observed 2 hours post injection. Tumor:muscle and tumor:blood ratios were shown to be 8 and 6 respectively. Conclusion: 64Cu-PTSM prepared in this report is a good candidate for tumor therapy as well as diagnosis for national use.
|Journal||Iranian Journal of Nuclear Medicine|
|Publication status||Published - 31 Jul 2007|